Pilot study on the treatment of cyclical mastodynia with Quinagolide.
In a pilot clinical trial on 52 patients, 75 microg Quinagolide given once per day was administered for the treatment of cyclical mastodynia. Linear analogue charts were used for the assessment of response. Decrease in breast pain, heaviness, tenderness and serum prolactin level on the one hand, and increases in the serum estradiol and progesterone levels on the other hand were noted after 3 and 6 months administration, and were statistically significant. Statistical analysis was performed by Paired t-test or Wilcoxon test. One-Way Anova Repeated Measures and Wilcoxon test and analysis of Covariance model. The beneficial effect of Quinagolide also lasted after the cessation of treatment. Fourteen patients dropped out during treatment. Adverse effects like nausea, low blood pressure, dizziness and constipation were rarely reported.
Ioannidou-Mouzaka
L
L
Iaso Maternity Hospital, Athens, Greece.
Niagassas
M
M
Galanos
A
A
Kalovidouris
A
A
D000328:Adult; D000634:Aminoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D001941:Breast Diseases / Q000188:drug therapy*; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008597:Menstrual Cycle; D008875:Middle Aged; D010146:Pain; D010507:Periodicity; D010865:Pilot Projects; D016896:Treatment Outcome
D000634:Aminoquinolines; D018491:Dopamine Agonists; C046650:quinagolide